ClearBridge Investments released its second-quarter 2025 investor letter, noting growth stocks leading the stock market rebound. The Russell 3000 Growth Index rose 17.6%, outperforming the Value Index by 1,300 basis points. ClearBridge’s Strategy underperformed its benchmark. Check the fund’s top five holdings for insights into its 2025 picks.

Novo Nordisk A/S (NVO) was highlighted in ClearBridge’s letter, with a one-month return of 15.67%. The stock closed at $56.46 on August 29, 2025, with a market cap of $254.044 billion. ClearBridge switched from Eli Lilly to Novo, citing Novo’s potential in the diabesity market.

Novo Nordisk A/S (NVO) is not among the 30 Most Popular Stocks Among Hedge Funds. 45 hedge fund portfolios held NVO at the end of Q2, down from 60 in the previous quarter. While NVO has investment potential, AI stocks may offer greater upside. For an undervalued AI stock, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: What Makes Novo Nordisk A/S (NVO) an Attractive Investment Compared to Competitors?